# A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Source: https://onco.cc/trials/nct06340568/  
OnCo record `nct06340568` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab pamirtecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by BioNTech SE, now recruiting.

## Summary

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer is a phase 3 interventional study registered as NCT06340568 by BioNTech SE, with 480 participants planned, started 2025-06-10 and due to reach its primary completion in 2028-03. Interventions recorded: BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06340568
- Phase: 3
- Setting: A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
- Sponsor: BioNTech SE
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT06340568: https://clinicaltrials.gov/study/NCT06340568

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Trastuzumab pamirtecan](https://onco.cc/drugs/trastuzumab-pamirtecan/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct06340568.json